AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...

SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has designated its ...

During the Neogene period, humanity’s primate ancestors held a genomic advantage for combating gout. A new study found that the gene effectively lowered levels of uric acid and prevented ...

The multi-centre, randomised, double-blind RUBY and TOPAZ studies are assessing the therapy’s performance against allopurinol.